EFFICACY OF SANDOSTATIN LAR AT A DOSE 10- 40 MG IN THE TREATMENT OF ACROMEGALY.
- Authors: Dreval' A.V.1, Vinogradova A.V.1, Perfil'ev A.V.1, Trigolosova I.V.1, Ilovayskaya I.A.1, Vinogradova AV1, Perfil'ev AV1, Trigolosova IV1, Ilovayskaya IA1
-
Affiliations:
- Issue: No 11 (2011)
- Pages: 75-79
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278935
- ID: 278935
Cite item
Full Text
Abstract
About the authors
Aleksandr Vasil'evich Dreval'
Anna Viktorovna Vinogradova
Andrey Valentinovich Perfil'ev
Irina Vladimirovna Trigolosova
Irena Adol'fovna Ilovayskaya
A V Vinogradova
A V Perfil'ev
I V Trigolosova
I A Ilovayskaya
References
- Melmed S. Medical progress: acromegaly. N Engl J Med 2006 355:2558-73.
- Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25:102-52.
- Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008;159:89-95.
- Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008;93:61-7.
- Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:737-40.
- Ayuk J, Sheppard MC. Does acromegaly enhance mortality? Rev Endocr Metab Disord 2007;9:33-39.
- Мельниченко Г.А., Пронин В.С. Современные схемы фармакотерапии акромегалии // Врач. 2008. № 8. С. 9-13.
- Молитвословова Н.Н. Акромегалия: современные достижения в диагностике и лечении // Проблемы эндокринологии. 2011. № 1. С. 46-59.
- Maiza JC, Vezzosi D, Matta M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 2007;67:282-89.
- Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91:1397-403.
- Shimon I, Yan X, Taylor JE, et al. 1997 Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 100:2386-92.
- Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009;94:1509-17.
- Древаль А.В., Камынина Т.С., Нечаева О.А., Покрамович Ю.Г. Московский областной регистр больных акромегалией // Проблемы эндокринологии. 2008. № 4. С. 27-31.
- Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90:4465-73.
- Colao A, Pivonello R, Auriemma RS, et al. Beneficial effect of dose escalation of octreotide LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007;157:579-87.